Fungi produce a number of natural products. Some are potent toxins, like the amanitins primarily responsible for the toxicity of the death cap fungus. Others are life-saving drugs such as penicillin. Because of that diversity, the genetics of fungi have generated much interest in recent years.
Many fungi have a wealth of genes encoding for far more natural products than they actually produce, says Robert Cichewicz and colleagues at the University of Oklahoma, Norman. The explanation is thought to be that when fungi do not need certain compounds, they inhibit the transcription of the DNA that codes for the proteins that make them, preventing their biosynthesis.
Knowing what these mystery compounds are could be very important for the development of new medicines, as well as for helping us to understand the ecological roles that fungi play, he says.
In a new study published in Organic & Biomolecular Chemistry they have shown that metabolic pathways that are normally ‘silent’ can be re-activated to make new compounds.
The DNA involved is inhibited by being scrunched up in a globular form called heterochromatin. To activate this DNA and turn on these ‘silent’ natural product pathways, the team decided to treat fungal cultures with small molecules that interfere with the formation of the heterochromatin – allowing the DNA to be transcripted.
To show their idea in action, the researchers took a culture of Cladosporium cladosporioides, a tidal pool fungus, and treated it separately with 5-azacytidine and suberoylanilide hydroxamic acid. Both treatments, says Cichewicz, dramatically changed the natural product output of the fungus, with two completely new natural products being isolated.
The new approach impresses Jon Clardy at the Harvard Medical School, Boston, US, who says that it could ‘greatly expand the suite of biologically active small molecules obtained from fungi’ and that it ‘capitalises on recent developments in drug discovery to increase the odds of discovering new drugs’.
The results also have important implications for research into fungi and other microorganisms, explains Cichewicz. Natural products are the means by which fungi ‘communicate’ with organisms around them, so we are in essence, he says, ‘discovering chemical means for listening to what fungi are saying’.
Article: Russell Williams et al., Org. Biomol. Chem., 2008, DOI: 10.1039/b804701d
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Nobel Prize Validates Chinese Medicine? Nope.
- Horse-Like Fetus From 48 Million Years Ago Discovered
- An Easy Problem
- Mother Jones Hates Scientists - And Their Bias Shows
- Wet Paleoclimate Of Mars Revealed By Ancient Lakes At Gale Crater
- What Do EU Countries Give Up When They Opt-out Of GMO Crops? And For Whom?
- Thank You Guido
- "Great piece Steve. While the potential for suffering and death in Africa especially thanks to this..."
- "I look forward to more threats and libel from you in the very near future. It's your stock in trade..."
- "Dear Mr. Campbell: Again you spin and dissemble. It was quite clear from the many tweets between..."
- "One of us does not know what libel means (hint: It is you). Calling me a felon and a fraud is libel..."
- "Dear Mr. Campbell: Your entry remains libelous, and I ask that you correct it. Regarding the tweets..."
- FDA-Approved Test for Meningitis is a Home Run
- Trends In Smoking – Chinese Men In Peril, American Women Get Better Cessation
- Counter-Point: Activists Operate By Outrage, Not Fear
- Whole Foods Recalls Organic Roquefort Cheeses After Listeria Found
- Suicide Tries Linked to Weight-Loss Surgery? Study Doesn’t Show
- Following Rules, Refreezing Thawed Meat is Safe
- Beetles provide clues about the genetic foundations of parenthood
- Trees to power: McMaster engineers build better energy storage device
- High dose chemo & stem cell transplantation results in long-term survival for amyloid patients
- 'Blind analysis' could reduce bias in social sciences papers
- Adoption of streamlined breast cancer treatment has stagnated, study finds